Recently, the American Heart Association published a Science Advisory that advocates performing screening renal angiography as part of cardiac catheterization on patients at high risk for renal artery stenosis (RAS) who are potential candidates for revascularization. 1 Although screening renal angiography is safe and convenient, is it useful? Several criteria have been established for evaluating whether a screening test is worthwhile. 2 These criteria include diagnostic yield, whether the test leads to overdiagnosis and overtreatment, whether there are harms of treatment, and finally, whether detecting the screened condition leads to improved survival. Screening renal angiography fails to meet each of these criteria, and should not be performed as a routine part of cardiac catheterization.
Diagnostic yield
Depending upon the series and definition of stenosis severity, RAS is found in 7-15% of patients undergoing coronary angiography. [3] [4] [5] Rather than looking at prevalence, one should determine whether the screening test identifies new patients with vascular disease who require initiation of therapy to reduce cardiovascular risk. Thus, if a patient has coronary artery disease (CAD; e.g. angina, prior coronary revascularization, a positive stress test) or a CAD equivalent (e.g. cerebrovascular disease, an abdominal aortic aneurysm, or peripheral arterial disease), the patient requires maximum medical therapy to reduce the risk of cardiovascular events but does not need further screening. Buller and colleagues examined the prevalence of RAS ≥70% in 837 patients undergoing cardiac catheterization. 4 Patients underwent screening renal angiography if they met at least one of the following criteria: resistant hypertension, renal impairment, 'flash' pulmonary edema, or atherosclerosis in other vascular territories. Significant CAD was identified in 719 patients. The renal angiogram identified only five patients as 'high-risk' who were not otherwise detected by the coronary angiogram. Thus, the diagnostic yield of screening angiography for identifying previously undiagnosed vascular disease in a selected population was only 0.6%.
Is the natural history of RAS known?
One of the rationales espoused in the AHA Science Advisory for performing screening angiography is that "progression or worsening of RAS occurs commonly, with occlusion and loss of renal function more likely with more severe renal stenoses." 1 Several studies refute this notion. [6] [7] [8] Crowley and colleagues examined progression of RAS in 1189 patients who underwent cardiac catheterization. Although significant disease progression occurred in 133 (11.1%) patients, only four progressed to total occlusion. 8 A retrospective study compared outcomes for 126 patients with incidental RAS ≥50% detected during angiography for peripheral arterial disease with 126 age-and sex-matched controls without RAS. 6 In the RAS cohort, 51% had ≥70% stenosis; the overall group had significantly lower creatinine clearance than controls. During the 10-year follow-up, none of the RAS patients required renal replacement therapy. Serum creatinine remained stable. 6 Stronger evidence comes from the Cardiovascular Health Study, a prospective study in which renal duplex scans were performed on 119 elderly, communitydwelling participants at baseline and at an 8-year follow-up. The annualized progression rate of renal stenosis was 1.3%/year. The rate of progression to significant renovascular disease was only 0.5%/year. None of the subjects with RAS at baseline progressed to 100% occlusion at follow-up. 7 Harms of screening (e.g. overdiagnosis, overtreatment)
The current treatment armamentarium of antiplatelet agents, lipid-lowering drugs, and angiotensin-converting enzyme inhibitors has enabled patients with CAD to live long enough to Vascular Medicine 2009; 14: 271-275 develop incidental RAS. Screening for RAS leads to overdiagnosis of lesions that would not produce signs or symptoms before the person dies of other causes. Overdiagnosis leads to overtreatment. For example, the impact of offering magnetic resonance angiography (MRA) has been evaluated as an alternative to invasive angiography to screen for renovascular disease. In the 5 years after MRA was marketed, there was a sixfold increase in the number of MRAs and a 350% increase in the number of patients who underwent renal artery angioplasty or stenting. 9 In many cases, the temptation to stent is immense: 17% of patients undergo renal artery stenting at the time of their screening renal angiogram; 43% of patients undergo stenting within 30 days of the screening angiogram. 10 But the 'see it, stent it' approach to RAS has lead to an explosion in the number of renal artery revascularization procedures. According to Medicare data from 1996 to 2000, the total volume of renal revascularization procedures increased 62% to 21,660. 11 Percutaneous interventions increased by 240% over the same time period.
Outcomes following renal artery revascularization follow the rule of thirds: one-third improve, one-third stabilize, one-third deteriorate. 12, 13 Selecting patients who will benefit from renal artery revascularization remains problematic. Renal resistive index < 0.80 was believed to predict favorable outcome following renal intervention but the findings have not been replicated. 14 Several small series suggest that brain natriuretic peptide, 15 renal flow reserve, 16 and renal blush grade 17 may predict outcome after renal stenting. These studies have not been reproduced in large, randomized trials. In many cases, it is mere coincidence that a patient with hypertension or renal insufficiency happens also to have severe RAS. The relationship between RAS and renal function is inconsistent: patients with widely patent renal arteries may have poor renal function, while those with bilateral highgrade stenosis may have preserved renal function. 18 Even after successful renal artery stenting, the glomerular filtration rate often remains unchanged. 19 The dangers of earlier treatment Complications of renal stenting include death, renal perforation, dissection, atheroembolization (e.g. renal failure, blue toe syndrome, livedo, bowel ischemia), and access complications including bleeding, hematoma, and pseudoaneurysm. It is the late complications, however, that occur most frequently and are most costly. Between 5.5% and 21% of patients who undergo renal artery stenting develop in-stent restenosis, which often leads to another round of unnecessary angiography, angioplasty, and stenting. 13, 20, 21 Does screening for RAS lead to increased survival?
Screening tests should lead to improved health outcomes. Examples of effective screening programs include abdominal ultrasound to detect abdominal aortic aneurysms in men between the ages of 65 and 75 years who have ever smoked. 22 Fecal occult blood testing, sigmoidoscopy, and colonoscopy have been instrumental in decreasing mortality from colon cancer. 23 Other screening tests are less useful. For example, the Mayo Lung Project found that performing serial sputum and chest X-rays to detect lung cancer was associated with decreased survival. 24 Recently, the US Preventive Services Task Force recommended against screening men ≥75 years of age for prostate cancer. 25 The detection of prostate cancer in this population demonstrates the hazards of overdiagnosis. These patients were overtreated with surgery, radiation, or chemotherapytherapies that carry significant risk of erectile dysfunction, urinary incontinence, bowel dysfunction, and death but did not improve quality of life or survival.
The AHA Science Advisory asserts that the poor prognosis associated with RAS "supports a strategy of increased awareness of the disease process and a need to identify RAS as early as possible." 1 To date, no study has shown a benefit to early (or late) treatment for RAS. Some have asserted that the presence of RAS ratchets up the risk of premature myocardial infarction, stroke and deathif only the physician was aware of the renal lesion he/she would be more vigilant. However, maximum therapy to reduce cardiovascular risk is a binary proposition: you're either on it or you're not. Thus, discovering RAS in patients who have disease in another arterial bed does not lead to more intensive therapy.
Stenting renal artery lesions does not lead to improved survival. Preliminary results from ASTRAL (Angioplasty and STent for Renal Artery Lesions), a randomized trial that examined outcomes following renal artery stenting, suggest that at 4 years' follow-up, renal stenting yields no survival benefit over medical therapy alone. 26 The time to first renal event, including acute renal failure, dialysis, transplant, nephrectomy, and renal death was also similar in both treatment arms. The ASTRAL trial has been criticized for enrolling only patients where the physician was unsure if the patient would benefit from revascularization. But even experts struggle with the decision of how to manage patients with renovascular disease. In the ANPARIA study, a multi-specialty expert panel made treatment recommendations in 1848 case scenarios of patients with RAS. The panel was uncertain whether to revascularize in 41% of scenarios. 27 The lack of consensus was attributed to the paucity of high-quality, randomized trials on managing renal artery disease. The vascular community awaits results from the Cardiovascular Outcomes in Renal Atherosclerotic Lesions (CORAL) trial, which tests the hypothesis that stenting atherosclerotic RAS in patients with systolic hypertension reduces the incidence of cardiovascular and renal events.
Another justification for screening renal angiography offered in the AHA Science Advisory is that atherosclerotic RAS is associated with a significant mortality hazard. This rationale is based largely on a study by Conlon et al. that suffers from several shortcomings. 28 First, nearly 50% of the patients who should have undergone a screening abdominal aortogram did not have one. Those patients were more likely to have a low ejection fraction, elevated serum creatinine, or a history of congestive heart failureconditions associated with increased mortality. Failure to include these patients may have produced a selection bias. The second flaw is that the two comparison groupsthose with ≥75% RAS and those withoutwere poorly matched. Patients with ≥75% RAS were a decade older and had more co-morbidities such as congestive heart failure, hypertension, and elevated creatinine than individuals with <75% RAS. It should come as no surprise that older patients with more comorbidities die sooner than younger, healthier patients. Finally, Conlon's group may have examined the wrong independent variable. Instead of RAS, the authors should have focused on chronic kidney disease (CKD).
CKD, defined as an estimated glomerular filtration rate (eGFR) ≤60 ml/min per 1.73 m 2 or urine albumin-creatinine ratio ≥30 mg/g (ACR), is associated with premature cardiovascular morbidity and mortality. 29 It is possible to discern which variable plays the greater role in survival -RAS or CKDby comparing outcomes in patients who have undergone renal artery revascularization. In a series of 139 patients who underwent surgical renal revascularization for the preservation of renal function, the risk of late death was increased 1.5-fold for each 1 mg/dl increment in preoperative creatinine. 30 CKD is also associated with increased mortality after renal artery stenting. In one series, survival at 3 years in patients with baseline creatinine ≤1.4 was 92%, whereas in patients with creatinine ≥2.0 survival was only 51%. 31 A subsequent study of 1058 patients who underwent successful Palmaz stenting confirmed the deleterious effects of CKD on survival. 32 Large population-based studies verify the association of CKD with premature cardiovascular events. Results from two community-based screening studiesthe National Kidney Foundation Kidney Early Evaluation Program (KEEP) and the National Health and Nutrition Examination Survey (NHANES)found a marked increase in myocardial infarction, stroke, and death in individuals with CKD. 33 Patients with both CAD and CKD are at far greater risk of premature death than those with either condition alone. 34 CKD is epidemic. The prevalence of CKD in the United States has risen from 10% during 1988-1994 to 13% during 1999-2004. 35 The AHA has recommended that patients with CKD and end-stage renal disease be placed in the 'highest risk' category and receive aggressive preventative therapy. 36 Fortunately, CKD is readily diagnosed by measuring a serum creatinine, which is performed on nearly every patient who undergoes cardiac catheterization (for patients under the age of 60, the urinealbumin-creatinine ratio is more likely to be the positive screening test than eGFR 33 ). The prevalence of CKD in 1007 patients who underwent cardiac catheterization was 25.7%. 37 Thirteen percent of the patients who did not have CAD had CKD. Thus, the diagnostic yield of serum creatinine to detect a high-risk condition in patients undergoing cardiac catheterization was 13%.
The goal of any screening program is to identify a life-threatening disease and then improve quality of life or survival through treatment. As yet, there is no evidence that medical therapy alters prognosis in patients with RAS. Intensity of therapy for patients already diagnosed with cardiovascular disease is not increased if renal artery disease is detected. Once diagnosed, many patients with RAS undergo renal revascularization, even though it remains nearly impossible to predict which patients will benefit from intervention. Other than needlessly tempting interventionalists, there appears to be no benefit in screening for RAS. The most sensible program for identifying patients at high-risk for premature myocardial infarction, stroke, and death is to screen for chronic kidney disease and perform coronary angiography. This strategy will identify nearly 100% of patients who require intensive therapy to decrease cardiovascular risk.
